Lupin moves up on getting USFDA’s tentative approval for Siponimod Tablets
Lupin is currently trading at Rs. 2096.50, up by 4.55 points or 0.22% from its previous closing of Rs. 2091.95 on the BSE.
The scrip opened at Rs. 2098.35 and has touched a high and low of Rs. 2104.05 and Rs. 2083.90 respectively. So far 7380 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2106.00 and Rs. 2055.75 respectively. The current market cap of the company is Rs. 95481.57 crore.
The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 47.06% and 6.06% respectively.
Lupin has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Siponimod Tablets, 0.25 mg, 1 mg and 2 mg. This product would be manufactured at Lupin’s Pithampur facility in India.
Siponimod Tablets, 0.25 mg, 1 mg and 2 mg are bioequivalent to Mayzent Tablets, 0.25 mg, 1 mg and 2 mg of Novartis Pharmaceuticals Corporation, and indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults. Siponimod Tablets (RLD Mayzent) had estimated annual sales of $195 million in the U.S. (IQVIA MAT October 2025).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
